Abstract
Background/objectives:
Metabolic dysfunction–associated fatty liver disease (MAFLD) and subclinical hypothyroidism (SCH) increasingly co-occur in adolescents, yet their inter-relationship and clinical relevance remain uncertain.
Objective:
To synthesize evidence on epidemiologic associations, shared mechanisms, and care implications linking MAFLD and SCH in youth.
Methods:
We conducted a structured review of PubMed, Embase, Web of Science, and the Cochrane Library from inception to December 31, 2024, focusing on pediatric observational studies and mechanistic or interventional data relevant to adolescents. Two reviewers screened studies and extracted design, diagnostics, exposures (TSH/thyroid hormones), outcomes (steatosis severity, fibrosis, liver enzymes), and adjusted effect estimates. Risk of bias was narratively assessed for observational designs.
Results:
Pediatric cohorts consistently report a positive association between higher TSH (within the reference or mildly elevated range) and hepatic steatosis severity, with several studies indicating a dose–response gradient. Mechanistic evidence suggests TSHR–SREBP-1c signaling, insulin resistance, adipokine imbalance, low-grade inflammation, and gut–liver–thyroid crosstalk as plausible pathways. Adult interventional data show that levothyroxine therapy for SCH can modestly reduce liver fat and aminotransferases; however, pediatric trials are lacking. Definitions, diagnostic modalities, and confounding control vary across studies, and most pediatric evidence is cross-sectional, limiting causal inference.
Conclusions:
In adolescents, MAFLD and SCH appear linked through metabolic and endocrine pathways, but causality remains unproven. Risk-based screening may be warranted—thyroid testing in MAFLD and targeted liver assessment in persistent SCH—while longitudinal cohorts and pediatric trials are needed to define thresholds for intervention and potential benefits of endocrine management.
Highlights
Synthesizes adolescent evidence linking MAFLD and SCH and maps shared mechanisms.
TSH may drive hepatic lipogenesis via TSHR–SREBP-1c signaling, independent of overt hypothyroidism.
Pediatric studies show higher SCH prevalence/TSH levels with increasing steatosis severity.
Causal mediation suggests TSH partially mediates obesity's effect on MAFLD risk in youth.
Persistent TSH elevation associates with histologic progression; adult LT4 trials improve liver fat and enzymes, but pediatric interventional data are lacking.
Evidence remains largely cross-sectional; priorities include longitudinal and interventional pediatric studies to establish causality and guide risk-based screening.
Introduction
Pediatric obesity has become a global epidemic, fueling a parallel rise in metabolic and endocrine disorders among adolescents. Two conditions that frequently coexist in this population—metabolic dysfunction-associated fatty liver disease (MAFLD) and subclinical hypothyroidism (SCH)—share overlapping metabolic features and may influence each other's onset and progression (1, 2). MAFLD, a redefinition of nonalcoholic fatty liver disease (NAFLD), is diagnosed when hepatic steatosis is present alongside at least one metabolic abnormality, such as obesity, insulin resistance, or dyslipidemia. In adolescents, it is now the most common chronic liver disease, often detected incidentally during imaging or routine metabolic screening (3).
In parallel, SCH—characterized by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (FT4)—is increasingly reported in overweight and obese youth. Although sometimes regarded as benign or transient, SCH has been linked to adverse metabolic profiles, including higher body mass index (BMI), dyslipidemia, and impaired insulin sensitivity (4, 5). These abnormalities closely mirror MAFLD risk factors. Beyond association, experimental data suggest that elevated TSH may directly promote hepatic lipid deposition by stimulating hepatocyte lipogenesis, even when circulating thyroid hormone levels are normal (6, 7). Nevertheless, pediatric-specific evidence remains limited, and the direction of causality is unclear (8).
Given the long-term hepatic and cardiovascular risks of both conditions, clarifying their interplay during adolescence—a critical developmental period for metabolic programming—is clinically important. This review synthesizes current evidence on the association between SCH and MAFLD in adolescents, explores potential shared mechanisms, and identifies priorities for future clinical and translational research.
Methods
Search strategy and selection. We searched PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library using controlled vocabulary and keywords for (subclinical hypothyroidism OR TSH), (MAFLD/MASLD OR fatty liver OR steatosis), and (adolescents OR youth OR pediatric). Records were deduplicated; two reviewers independently screened titles/abstracts and full texts with adjudication by a third reviewer. A PRISMA 2020 flow diagram summarizes screening (Supplementary Figure S1). PRISMA counts reflect only pediatric primary studies included in the qualitative synthesis; adult interventional trials, mechanistic studies, and narrative reviews were cited for context and not counted as included studies.
Inclusion criteria: (i) participants ≤18 years or clearly pediatric populations; (ii) exposure: subclinical hypothyroidism (elevated TSH with normal free T4); (iii) outcome: MAFLD/MASLD or hepatic steatosis defined by imaging, biomarkers, or clinical criteria; (iv) study design: observational (cross-sectional, cohort, case-control) or trials; (v) reports association or relevant mechanistic data.
Exclusion criteria: adult-only studies; overt hypothyroidism or thyroid treatment without SCH subgroup; non-human studies unless mechanistic context only; case reports/series without comparator; abstracts lacking data; duplicate cohorts without unique analyses.
Risk of bias was assessed by two reviewers using design-appropriate tools: the Newcastle–Ottawa Scale (NOS) for case–control and cohort studies (Nichols, Untalan) and the JBI analytical cross-sectional checklist for cross-sectional studies (Choi, Kaltenbach, Xue). (Supplementary Table S1, S2); we did not dichotomize studies by arbitrary score thresholds.
Overview of MAFLD in adolescents
MAFLD is a recently defined clinical entity that reframes hepatic steatosis by emphasizing its metabolic underpinnings. Unlike the older term nonalcoholic fatty liver disease (NAFLD), which is largely defined by excluding secondary causes, MAFLD is diagnosed when hepatic fat accumulation occurs in the presence of metabolic risk factors such as obesity, insulin resistance, dyslipidemia, or type 2 diabetes (9, 10). In pediatric patients, the diagnosis requires imaging or histological evidence of steatosis along with at least one feature of metabolic dysfunction (3). This approach better reflects the pathophysiological profile of adolescents, especially given the global rise in childhood obesity (1).
The prevalence of MAFLD in adolescents varies widely. Population-based estimates range from roughly 7% in general pediatric cohorts to over 30% in obese youth. A systematic review and meta-analysis by Anderson et al. (2015) reported a pooled prevalence of 2.6%–10% in the general pediatric population and up to 34% in obese children, reflecting the strong influence of adiposity on disease burden (1). More recent data suggest that in some clinical cohorts, particularly those using MAFLD diagnostic criteria, prevalence may exceed 50% among high-risk subgroups-such as male adolescents and individuals of Hispanic or Asian descent (11, 12). This variation reflects not only genetic predisposition but also lifestyle and environmental factors, including reduced physical activity, greater consumption of ultra-processed foods, and the growing burden of insulin resistance during puberty (13).
The pathogenesis of MAFLD is multifactorial, with hepatic insulin resistance at its core. Disrupted insulin signaling in hepatocytes promotes de novo lipogenesis, suppresses fatty acid oxidation, and increases the influx of free fatty acids from adipose tissue lipolysis. Together, these processes drive triglyceride accumulation within the liver. As steatosis advances, secondary insults—such as oxidative stress, endoplasmic reticulum stress, and inflammatory signaling—contribute to hepatocellular injury, nonalcoholic steatohepatitis (NASH), and ultimately fibrosis (13, 14).
Host genetics further modulate susceptibility. Variants in PNPLA3 and TM6SF2 have been linked to greater hepatic fat content and fibrosis risk in both adults and children (15, 16). The gut–liver axis has also emerged as a key player. Dysbiosis, characterized by reduced microbial diversity, increased gut permeability, and altered bile acid metabolism, may amplify systemic inflammation and accelerate hepatic lipid deposition (17, 18).
Clinically, adolescent MAFLD is often silent, detected only through elevated aminotransferase levels or incidental imaging findings. Yet even mild disease carries long-term consequences, including heightened risks of type 2 diabetes, cardiovascular disease, and progressive liver injury (18–20). Early recognition is therefore crucial—particularly in adolescents with coexisting endocrine conditions such as SCH, which may further compound metabolic and hepatic stress (21, 22).
Overview of subclinical hypothyroidism in adolescents
SCH refers to a mild form of thyroid dysfunction in which serum TSH levels are elevated, but free thyroxine (FT4) concentrations remain within the reference range. Often asymptomatic, SCH is being recognized more frequently in adolescents, particularly in those with obesity, insulin resistance, or autoimmune thyroid disease (23, 24). The prevalence appears to rise during puberty—especially among girls—likely reflecting both physiological hormonal shifts and underlying endocrine susceptibility (25). In obese pediatric cohorts, reported rates range from 10% to 20%, compared with only 1%–4% in the general adolescent population (21).
Autoimmune thyroiditis, most commonly Hashimoto's thyroiditis, is the leading cause of SCH in this age group and is characterized by the presence of anti-thyroid peroxidase (TPO) and anti-thyroglobulin (TG) antibodies (26). Other contributors include excessive iodine intake, genetic predisposition, and hormonal fluctuations during puberty. Although FT4 levels remain normal, some adolescents may experience tissue-level hypothyroidism due to impaired conversion of thyroxine (T4) to triiodothyronine (T3) or reduced peripheral sensitivity to thyroid hormones (27).
Increasing evidence indicates that SCH, even in its subclinical form, is associated with significant metabolic alterations (28). Adolescents with SCH frequently exhibit increased body mass index (BMI), dyslipidemia characterized by elevated LDL cholesterol and total cholesterol levels, impaired glucose tolerance, and reduced insulin sensitivity. These metabolic disturbances mirror the key features of MAFLD pathogenesis, suggesting potential bidirectional interaction (29). In particular, elevated TSH—once considered a mere biomarker—may itself exert direct effects on metabolic tissues, including hepatocytes and adipocytes. TSH has been shown to influence hepatic lipid accumulation, modulate adipokine secretion, and activate inflammatory pathways, which may compound the risk of hepatic steatosis and metabolic syndrome in susceptible youth (30).
The natural course of SCH in adolescents is variable, with many cases—particularly those without thyroid autoantibodies and with TSH levels <10 mIU/L—showing spontaneous normalization over time (31–33). Treatment thresholds therefore remain debated in pediatrics. While TSH ≥10 mIU/L is often used as a pragmatic cut-off to consider levothyroxine in persistently elevated or symptomatic cases, management of milder elevations (TSH ∼4–10 mIU/L) is individualized. Decisions typically incorporate TSH trajectory across repeat measurements, clinical symptoms, goiter or thyroid autoimmunity (anti-TPO), lipid profile and insulin resistance, pubertal status, and overall cardiometabolic risk. Persistent or progressive SCH—especially in the presence of thyroid autoimmunity—is more likely to progress to overt hypothyroidism and may aggravate coexisting metabolic disturbances (34). Current pediatric guidelines do not mandate universal treatment of SCH, but rather support individualized decision-making and periodic reassessment (35). In adolescents with MAFLD, however, SCH should not be regarded as an incidental finding. Given the shared metabolic and inflammatory milieu, adolescents with SCH—particularly those with obesity or other metabolic risk factors—may warrant targeted hepatic assessment, whereas those with MAFLD and elevated TSH should receive closer endocrine evaluation. Recognizing this bidirectional overlap may help refine risk stratification and promote integrated, early interventions during this critical window of metabolic development.
Pathophysiological connections between MAFLD and SCH
Recent evidence indicates that MAFLD and SCH in adolescents are not merely coincidental but are mechanistically linked through interconnected endocrine–metabolic pathways. Both share common risk factors—obesity, insulin resistance, and low-grade systemic inflammation—and may exacerbate one another through bidirectional feedback loops.
TSH-mediated hepatic effects appear to be a key link. Hepatocytes express TSH receptors (TSHR), and TSHR activation stimulates lipogenic transcription factors such as sterol regulatory element-binding protein-1c (SREBP-1c), enhancing triglyceride synthesis and fat accumulation (6). This signaling cascade promotes triglyceride synthesis and hepatic fat accumulation, even in euthyroid individuals (36). In adolescents with SCH, chronically elevated TSH may thus contribute directly to the pathogenesis of MAFLD, amplifying hepatic steatosis through enhanced de novo lipogenesis (37).
Insulin resistance serves as another major bridge. In MAFLD, impaired insulin signaling promotes increased free fatty acid flux to the liver, reduced β-oxidation, and triglyceride storage. SCH may worsen insulin resistance through reduced T3-mediated glucose transporter activity, mitochondrial dysfunction, and altered adipokine signaling (37). Adolescents with SCH often exhibit elevated fasting insulin and higher homeostatic model assessment for insulin resistance (HOMA-IR) scores, both of which are linked to liver fat accumulation (38).
Chronic low-grade inflammation further connects the two disorders. In MAFLD, hepatocyte injury and lipotoxicity trigger pro-inflammatory cytokine release, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) (38). In SCH—particularly of autoimmune origin—systemic inflammation is also elevated, even without overt hypothyroid symptoms (39). This systemic inflammatory milieu may perpetuate hepatic dysfunction and thyroid hormone resistance, establishing a pathological feedback loop. Moreover, dysfunction of adipose tissue in both conditions contributes to an imbalance in adipokines such as leptin, adiponectin, and resistin.
Adipokine dysregulation adds another layer of interaction. In both conditions, leptin resistance can stimulate TSH secretion and hepatic lipogenesis, while low adiponectin levels reduce fatty acid oxidation and worsen insulin resistance (38, 40). These adipose-derived signals may also disturb hypothalamic–pituitary–thyroid (HPT) axis regulation.
An emerging concept is the gut–liver–thyroid axis. Alterations in gut microbiota composition, intestinal permeability, and bile acid metabolism—frequent in obese adolescents—may influence both hepatic lipid handling and thyroid function (41). Microbial metabolites such as short-chain fatty acids and secondary bile acids can modulate metabolic and endocrine pathways (42). Although pediatric data are limited, this axis provides a plausible mechanistic framework for the co-occurrence of MAFLD and SCH and may represent a novel therapeutic target (43).
Together, these pathophysiological mechanisms underscore a multifactorial and bidirectional relationship between SCH and MAFLD in adolescents. Rather than isolated entities, the two conditions appear to converge at the nexus of hormonal regulation, metabolic signaling, and inflammatory activation. This evolving understanding highlights the need for integrated diagnostic and therapeutic strategies that consider the endocrine-liver interface in managing metabolic disorders in youth (Table 1).
Table 1
| Pathophysiological module | Key pathways | Impact on MAFLD | Impact on SCH |
|---|---|---|---|
| TSH and hepatic lipid metabolism (6) | TSH → TSHR → SREBP-1c ↑ → lipogenesis ↑ | Promotes hepatic lipid | Sustained TSH elevation |
| Insulin resistance (37) | ↓T3→↓GLUT expression →↑insulin resistance | Exacerbates hepatic metabolic dysfunction | Impaired T3 metabolic activity |
| Chronic low-grade inflammation (38) | ↑TNF-α/↑IL-6→liver injury & thyroid hormone resistance | Activates inflammation and hepatocyte injury | Inflammation disrupts thyroid hormone signaling |
| Adipokine imbalance (38, 40) | ↑Leptin/↑Resistin/↓Adiponectin → metabolic dysfunction | Increases lipogenesis and insulin | Dysregulation of the HPT axis |
| Gut–liver–thyroid axis (41) | SCFA/bile acid dysregulation→liver and thyroid function affected | Microbiota-derived signals promote steatosis | Microbiota affects TSH regulation and hormone |
Pathophysiological mechanisms linking subclinical hypothyroidism and MAFLD in adolescents.
Evidence from recent studies
A growing body of clinical evidence supports the association between SCH and MAFLD in adolescents. Although most available studies are cross-sectional or retrospective in design, their findings consistently suggest that thyroid dysfunction, particularly elevated TSH levels, is linked to hepatic steatosis and metabolic disturbances in obese youth.
Several observational studies have reported a higher prevalence of SCH among adolescents with MAFLD, and vice versa. In a multicenter retrospective study conducted by Choi et al. (44) involving 428 Korean children with NAFLD, 13.6% were diagnosed with SCH. The prevalence of SCH increased progressively with liver disease severity, from 1.1% in mild steatosis to 55.4% in severe cases. Multivariate analysis demonstrated that severe steatosis (OR = 98.35, 95% CI: 22.4–431.9) and elevated aspartate aminotransferase-to-platelet ratio index (APRI) were independent predictors of SCH. These findings highlight a possible dose-response relationship between hepatic fat accumulation and thyroid dysfunction. Similarly, Xue et al. (45) examined 141 obese boys and found that those with mild SCH (n = 47) exhibited a higher prevalence of NAFLD and metabolic syndrome compared to euthyroid counterparts. They also had lower IGF-1 SDS scores and higher BMI SDS, with multivariate models confirming both as independent predictors of SCH. These results underscore a potential link between impaired growth factor signaling, adiposity, and thyroid dysfunction.
Longitudinal insights are limited but emerging. In a retrospective cohort study by Untalan et al. (46), SCH was significantly more common in adolescents with imaging- or biopsy-confirmed MAFLD. Moreover, persistent TSH elevation over time was associated with histological progression of liver disease, including worsening steatosis and fibrosis. These findings suggest that SCH may not only coexist with MAFLD but also influence its natural history. Beyond associations, attempts have been made to explore causality using statistical mediation analysis. A study applying causal mediation modeling (47) among children with biopsy-proven NAFLD revealed that TSH in the highest quartile (>2.35 mIU/L) conferred a 4.6-fold increased odds of NAFLD. Importantly, TSH accounted for approximately 34% of the total effect of modified BMI-z on NAFLD risk, with 16% mediated indirectly through TSH and 18% reflecting a direct effect independent of obesity. These findings imply that TSH may serve as a partial mediator between obesity and fatty liver, rather than being a mere bystander.
Narrative reviews have further reinforced the biological plausibility of a bidirectional relationship between SCH and MAFLD in adolescents. For example, Calcaterra et al. (39) proposed a feedback model in which obesity-driven inflammation induces SCH, while elevated TSH promotes hepatic lipogenesis and insulin resistance. Kaltenbach et al. (48) also reported that among 332 obese children, those with hepatic steatosis had significantly higher TSH levels. Additional studies have observed elevated levels of total and free triiodothyronine (T3) with concomitant reductions in FT4 in MAFLD patients, potentially reflecting tissue-level hypothyroidism and adaptive thyroidal responses to metabolic stress.
Although most existing data derive from observational studies, preliminary interventional trials in adults offer additional support for a causal link. A post hoc analysis of a randomized controlled trial by Liu et al. (49) showed that levothyroxine (LT4) therapy significantly reduced NAFLD prevalence in adults with significant SCH (from 48.5% to 24.2%, p = 0.041), and improved liver enzymes. In mild SCH patients with dyslipidemia, LT4 supplementation led to modest improvements in hepatic and metabolic parameters. Consistent findings were reported by Mahran et al. (50) in a prospective RCT, where adult patients with SCH and MASLD showed significant improvements in liver fat content, steatosis grades (by ultrasound and CAP), liver enzymes, BMI, and lipid profiles following LT4 treatment. For example, MASLD prevalence declined to 50% in the significant SCH-LT4 group (p = 0.001) and to 60% in the mild SCH-LT4 group (p = 0.025), while the untreated group showed only non-significant improvement.
Collectively, these findings support a consistent association between SCH and MAFLD in adolescents, with emerging evidence—both mechanistic and interventional—suggesting a potential causal pathway mediated through TSH. However, the heterogeneity of study designs, populations, and diagnostic criteria limits the strength of inference. Well-powered, prospective studies and pediatric-specific randomized trials are needed to confirm temporality and elucidate whether targeting thyroid dysfunction may alter the trajectory of pediatric fatty liver disease (Table 2).
Table 2
| Study | Sample size | Design | Key findings |
|---|---|---|---|
| Choi et al., (44) | 428 children | Multicenter retrospective cross-sectional | SCH prevalence rose with steatosis severity (1.1% to 55.4%); severe steatosis and APRI were independent predictors |
| Xue et al., (45) | 141 obese boys | Single-center cross-sectional | Mild SCH associated with NAFLD, MetS; lower IGF-1 SDS and higher BMI SDS were independent predictors |
| Untalan et al., (46) | Not specified; adolescents with biopsy/imaging-confirmed MAFLD | Retrospective cohort | Persistent TSH elevation associated with histologic progression (steatosis, fibrosis) |
| Causal mediation modeling | 4,133 children (66 NAFLD cases, 4,067 controls) | Causal mediation analysis (case-control) | TSH Q4 (>2.35 mIU/L) conferred 4.6× NAFLD risk; 34% of BMI-z effect mediated through TSH |
| Calcaterra et al., (39) | Narrative review | Review | Proposed feedback loop: obesity-induced inflammation causes SCH; TSH promotes hepatic lipogenesis and IR |
| Kaltenbach et al., (48) | 332 obese children | Single-center cross-sectional | Children with steatosis had significantly higher TSH levels; TSH independently associated with NAFLD |
| Liu et al., (49) | 363 adults with SCH | Post hoc RCT analysis | LT4 reduced NAFLD prevalence (48.5% to 24.2%) and improved liver enzymes |
| Mahran et al., (50) | 182 adults with SCH + MASLD | Prospective RCT | LT4 significantly improved liver fat, BMI, lipids; MASLD declined to 50%–60% post-treatment |
Summary of studies exploring the association between subclinical hypothyroidism and MAFLD in adolescents.
Screening, risk assessment, and treatment implications
Given the emerging evidence linking SCH to MAFLD in adolescents, there is a compelling rationale for integrated screening strategies in high-risk populations. Routine evaluation of thyroid function—particularly measurement of serum TSH and FT4—may offer additional clinical insight in adolescents with hepatic steatosis, especially those with obesity, insulin resistance, or abnormal liver enzymes. Similarly, adolescents diagnosed with SCH, even in the absence of overt hypothyroid symptoms, should be considered for hepatic assessment using non-invasive tools such as abdominal ultrasonography or transient elastography. Early identification of concurrent liver and thyroid dysfunction could allow for timely lifestyle or pharmacological interventions aimed at preventing long-term metabolic complications.
TSH levels may also serve as surrogate biomarkers of systemic metabolic stress and hepatic vulnerability. Incorporating thyroid function tests into standard metabolic screening panels for adolescents with obesity or features of the metabolic syndrome may enhance risk stratification. Furthermore, monitoring longitudinal trends in TSH could aid in predicting progression or resolution of hepatic steatosis, particularly in patients undergoing weight management or pharmacologic therapy.
Despite increasing recognition of the SCH–MAFLD interplay, the optimal management of adolescents with both conditions remains uncertain. Current guidelines generally recommend a conservative approach to SCH, with treatment typically reserved for individuals with TSH >10 mIU/L, overt hypothyroidism, or significant symptom burden (51). However, in the context of MAFLD, this threshold may warrant reevaluation. If elevated TSH actively contributes to hepatic lipid accumulation, as suggested by mechanistic and mediation studies, targeted thyroid hormone therapy—such as low-dose levothyroxine—could offer hepatic as well as metabolic benefit (52). Preliminary adult studies have reported improvements in liver fat content and aminotransferase levels following normalization of TSH with levothyroxine (49, 50, 53). While pediatric data are limited, such findings support the need for clinical trials assessing whether thyroid-directed treatment can modify the course of MAFLD in adolescents with persistent SCH (39). Importantly, any pharmacological intervention should be balanced against the potential for overtreatment, especially given the fluctuating and often transient nature of SCH in youth.
In parallel, lifestyle modification remains the cornerstone of management for both conditions. Caloric restriction, increased physical activity, and reduction in screen time have all been shown to improve both thyroid function and hepatic steatosis in adolescents. Even modest weight loss can lead to reductions in TSH levels and improvements in liver fat content (54). These findings reinforce the value of comprehensive lifestyle programs as first-line therapy, with potential for dual endocrine and hepatic benefit.
From a public health perspective, awareness of the endocrine–hepatic connection in pediatric obesity is essential. Clinicians should be alert to subtle endocrine abnormalities that may signal increased risk for liver disease, while educational efforts targeting families and schools should emphasize the systemic consequences of childhood metabolic dysfunction. Establishing integrated care pathways that include or liver assessment for adolescents with SCH (38).
Future research directions
Although evidence increasingly hints at a connection betweencc SCH and MAFLD in adolescents, many aspects remain unresolved. The field still lacks studies that can unravel not only if the two conditions are related, but also how and in what order they develop.
A logical next step would be to follow adolescents over several years, tracking thyroid hormone levels, liver fat content, and key metabolic markers at multiple time points. Such longitudinal designs could help distinguish whether thyroid dysfunction emerges before, alongside, or after hepatic steatosis. These studies would also need to account for important modifiers—pubertal stage, sex steroid levels, and genetic predisposition—so as to avoid spurious associations. In some cases, genetic approaches like Mendelian randomization might help to test whether a lifelong tendency toward higher TSH is inherently tied to greater liver fat accumulation.
Another issue worth addressing is whether intervention can change the course of disease. Could correcting thyroid function—using levothyroxine or other targeted strategies—translate into measurable improvements in liver health? Randomized trials could explore this, looking at outcomes such as reduced hepatic fat fraction on MRI, lower aminotransferase concentrations, or improvements in non-invasive fibrosis scores. It would also be valuable to see whether pairing thyroid treatment with lifestyle modification or insulin-sensitizing agents yields better results than either option alone.
Until such evidence is available, any firm recommendations on screening or treatment in this young population would be premature. The answers, however, will be critical for shaping prevention and management strategies in a group that stands to benefit from early and effective intervention.
Mechanistic and translational research
Understanding how thyroid dysfunction shapes hepatic lipid metabolism in adolescents requires bridging mechanistic research with translational applications. Recent work indicates that TSH may directly activate hepatocyte receptors, influencing key regulators such as SREBP-1c, PPAR-γ, and AMPK, which collectively govern lipid synthesis, oxidation, and storage. Thyroid hormones also affect mitochondrial biogenesis and redox balance, potentially altering vulnerability to oxidative stress and lipotoxic injury. In addition, metabolic tissues may act as an interface where adipokines, inflammatory mediators, and thyroid hormone receptors converge, although the sequence and relative importance of these interactions remain to be established. To capture adolescent-specific physiology, experimental models such as induced pluripotent stem cell–derived hepatocytes and juvenile animal models should be prioritized over adult-based systems.
An emerging but underexplored area is the gut–liver–thyroid axis, which integrates microbial, hepatic, and endocrine signaling. Evidence from adult and limited pediatric studies suggests that microbial metabolites—such as short-chain fatty acids, secondary bile acids, and lipopolysaccharides—can modulate both hepatic steatosis and thyroid hormone activity (55, 56). Given that adolescence is a period of dynamic gut microbiota development, disruptions in this axis could have unique consequences for metabolic health. Future studies should combine metagenomic sequencing, metabolomic profiling, and intestinal permeability assays to define microbial and metabolic signatures associated with concurrent SCH and MAFLD in youth. Interventional approaches, including probiotics, prebiotics, or dietary fiber supplementation, could then test whether modulation of the gut–liver–thyroid axis can improve both hepatic and thyroid outcomes.
Finally, the absence of pediatric-specific clinical guidelines poses a major limitation for practice. Current thresholds for diagnosing and treating SCH are largely extrapolated from adult populations and may not reflect developmental and pubertal variations in TSH physiology. Research should aim to determine age-appropriate TSH cut-offs that correlate with increased liver risk, establish evidence-based screening intervals for thyroid function in adolescents with obesity or hepatic steatosis, and clarify when levothyroxine therapy is warranted in the setting of hepatic involvement. Such efforts would lay the groundwork for precision screening and personalized interventions that address the complex interplay between endocrine and hepatic health in adolescence.
Statements
Author contributions
XH: Writing – original draft. WS: Writing – review & editing. GX: Writing – review & editing. WL: Investigation, Visualization, Writing – review & editing. NY: Investigation, Visualization, Writing – review & editing. GY: Conceptualization, Supervision, Writing – review & editing. JQ: Conceptualization, Supervision, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2026.1696331/full#supplementary-material
Abbreviations
MAFLD, metabolic dysfunction-associated fatty liver disease; SCH, subclinical hypothyroidism; TSH, thyroid-stimulating hormone; FT4, free thyroxine; BMI, body mass index; NAFLD, nonalcoholic fatty liver disease; T3, Triiodothyronine; HOMA-IR, homeostatic model assessment for insulin resistance; TNF-α, tumor necrosis factor alpha; IL-6, Interleukin 6; TSHR, thyroid-stimulating hormone receptor; SREBP-1c, sterol regulatory element-binding protein-1c; GLUT, glucose transporter; HPT axis, hypothalamic–pituitary–thyroid axis; SCFA, short-chain fatty acids; ALT, alanine aminotransferase; AST, aspartate aminotransferase; RCT, randomized controlled trial; MRI-PDFF, magnetic resonance imaging–proton density fat fraction; PPAR-γ, peroxisome proliferator-activated receptor gamma; AMPK, AMP-activated protein kinase; TPO, thyroid peroxidase; TG (antibody), thyroglobulin; SDS, standard deviation score; IGF-1, insulin-like growth factor 1; APRI, aspartate aminotransferase-to-platelet ratio index; LT4, levothyroxine; CAP, controlled attenuation parameter; MR, mendelian randomization.
References
1.
AndersonELHoweLDJonesHEHigginsJPLawlorDAFraserAet alThe prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. (2015) 10(10):e0140908. 10.1371/journal.pone.0140908
2.
PacificoLNobiliVAnaniaCVerdecchiaPChiesaC. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol. (2011) 17(26):3082–91. 10.3748/wjg.v17.i26.3082
3.
VosMBAbramsSHBarlowSECaprioSDanielsSRKohliRet alNASPGHAN Clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the north American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. (2017) 64(2):319–34. 10.1097/MPG.0000000000001482
4.
ReinehrTde SousaGAndlerW. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J Clin Endocrinol Metab. (2006) 91(8):3088–91. 10.1210/jc.2006-0095
5.
GrandoneASantoroNCoppolaFCalabròPPerroneLDel GiudiceEMet alThyroid function derangement and childhood obesity: an Italian experience. BMC Endocr Disord. (2010) 10:8. 10.1186/1472-6823-10-8
6.
YanFWangQLuMChenWSongYJingFet alThyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity. J Hepatol. (2014) 61(6):1358–64. 10.1016/j.jhep.2014.06.037
7.
SongYXuCShaoSLiuJXingWXuJet alThyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4α/CYP7A1 axis. J Hepatol. (2015) 62(5):1171–9. 10.1016/j.jhep.2014.12.006
8.
ChakerLBiancoACJonklaasJPeetersRP. Hypothyroidism. Lancet. (2017) 390(10101):1550–62. 10.1016/S0140-6736(17)30703-1
9.
EslamMNewsomePNSarinSKAnsteeQMTargherGRomero-GomezMet alA new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. (2020) 73(1):202–9. 10.1016/j.jhep.2020.03.039
10.
EslamMSanyalAJGeorgeJ. MAFLD: a consensus-driven proposed Nomenclature for metabolic associated fatty liver disease. Gastroenterology. (2020) 158(7):1999–2014.e1. 10.1053/j.gastro.2019.11.312
11.
WelshJAKarpenSVosMB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr. (2013) 162(3):496–500.e1. 10.1016/j.jpeds.2012.08.043
12.
SchwimmerJBDeutschRKahenTLavineJEStanleyCBehlingCet alPrevalence of fatty liver in children and adolescents. Pediatrics. (2006) 118(4):1388–93. 10.1542/peds.2006-1212
13.
CaliAMCaprioS. Ectopic fat deposition and the metabolic syndrome in obese children and adolescents. Horm Res. (2009) 71(Suppl 1):2–7. 10.1159/000178028
14.
LiuZZhangYGrahamSWangXCaiDHuangMet alCausal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. (2020) 73(2):263–76. 10.1016/j.jhep.2020.03.006
15.
BalcarLSemmlerGOberkoflerHZandanellSStrasserMDatzLet alPNPLA3 Is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center. Dig Liver Dis. (2022) 54(1):84–90. 10.1016/j.dld.2021.06.015
16.
XuMLiYZhangSWangXShenJZhangSet alInteraction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China. Ann Hepatol. (2019) 18(3):456–60. 10.1016/j.aohep.2018.10.005
17.
ScorlettiEWestALBhatiaLHoileSPMcCormickKGBurdgeGCet alTreating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatol. (2015) 63(6):1476–83. 10.1016/j.jhep.2015.07.036
18.
WuJTLiuSSXieXJLiuQXinYNXuanSYet alIndependent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease. Lipids Health Dis. (2020) 19(1):29. 10.1186/s12944-020-01207-9
19.
Di SessaA. Cembalo Sambiase SanseverinoNDe SimoneRFMarrapodiMMCirilloGUmanoGRet al, Association between non-alcoholic fatty liver disease and subclinical hypothyroidism in children with obesity. J Endocrinol Invest. (2023) 46(9):1835–42. 10.1007/s40618-023-02041-3
20.
KizivatTMaricIMudriDCurcicIBPrimoracDSmolicMet alHypothyroidism and nonalcoholic fatty liver disease: pathophysiological associations and therapeutic implications. J Clin Transl Hepatol. (2020) 8(3):347–53. 10.14218/JCTH.2020.00027
21.
SertAPirgonOAyparEYilmazHOdabasD. Subclinical hypothyroidism as a risk factor for the development of cardiovascular disease in obese adolescents with nonalcoholic fatty liver disease. Pediatr Cardiol. (2013) 34(5):1166–74. 10.1007/s00246-013-0638-z
22.
MantovaniANascimbeniFLonardoAZoppiniGBonoraEMantzorosCSet alAssociation between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Thyroid. (2018) 28(10):1270–84. 10.1089/thy.2018.0257
23.
DahlMOhrtJDFonvigCEKloppenborgJTPedersenOHansenTet alSubclinical hypothyroidism in Danish lean and obese children and adolescents. J Clin Res Pediatr Endocrinol. (2017) 9(1):8–16. 10.4274/jcrpe.3319
24.
KaraO. Influence of subclinical hypothyroidism on metabolic parameters in obese children and adolescents. Clin Exp Pediatr. (2020) 63(3):110–4. 10.3345/cep.2019.01536
25.
GawlikASuchKDejnerAZachurzokAAntoszAMalecka-TenderaEet alSubclinical hypothyroidism in children and adolescents: is it clinically relevant?Int J Endocrinol. (2015) 2015:691071. 10.1155/2015/691071
26.
AhmedMSBadrEAAssarMF. Visfatin (rs3801266) and adiponutrin (rs738409) gene single nucleotide polymorphisms in patients with hashimoto’s thyroiditis. Mol Biol Rep. (2025) 52(1):376. 10.1007/s11033-025-10437-y
27.
PacificoLBonciEFerraroFAndreoliGBascettaSChiesaCet alHepatic steatosis and thyroid function tests in overweight and obese children. Int J Endocrinol. (2013) 2013:381014. 10.1155/2013/381014
28.
ChenXDengSSenaCZhouCThakerVV. Relationship of TSH levels with cardiometabolic risk factors in US youth and reference percentiles for thyroid function. J Clin Endocrinol Metab. (2021) 106(3):e1221–30. 10.1210/clinem/dgaa900
29.
MintzioriGVenetiSPoppeKGoulisDGArmeniEErelCTet alEMAS Position statement: thyroid disease and menopause. Maturitas. (2024) 185:107991. 10.1016/j.maturitas.2024.107991
30.
DemirhanSPolatOMertM. The relationship between TSH levels, thyroid autoantibodies and atherogenic index of plasma, AST to platelet ratio index score, and fibrosis 4 index in patients with hypothyroidism. Acta Endocrinol (Buchar). (2023) 19(3):333–8. 10.4183/aeb.2023.333
31.
Murillo-VallésMMartinezSAguilar-RieraCGarcia-MartinMABel-ComósJYbernMLGet alSubclinical hypothyroidism in childhood, treatment or only follow-up?BMC Pediatr. (2020) 20(1):282. 10.1186/s12887-020-02177-8
32.
ValenziseMAversaTZirilliGSalzanoGCoricaDSantucciSet alAnalysis of the factors affecting the evolution over time of subclinical hypothyroidism in children. Ital J Pediatr. (2017) 43(1):2. 10.1186/s13052-016-0322-z
33.
AmouzegarA, Dehghani M, Abdi H, Mehran L, Masoumi S, Azizi F. Natural history of subclinical hypothyroidism and prognostic factors for the development of overt hypothyroidism: tehran thyroid study (TTS). J Endocrinol Invest. (2022) 45(12):2353–64. 10.1007/s40618-022-01876-6
34.
MetwalleyKAFarghalyHSSheriefTHusseinA. Vitamin D status in children and adolescents with autoimmune thyroiditis. J Endocrinol Invest. (2016) 39(7):793–7. 10.1007/s40618-016-0432-x
35.
SegniM. Disorders of the thyroid gland in infancy, childhood and adolescence. In: FeingoldKRAdlerRAAhmedSFAnawaltBBlackmanMR, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. (2000)– Accessed 2017 March 18.
36.
SinhaRABruinstroopESinghBKYenPMet alNonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid. (2019) 29(9):1173–91. 10.1089/thy.2018.0664
37.
FröhlichEWahlR. Insight into potential interactions of thyroid hormones, sex hormones and their stimulating hormones in the development of non-alcoholic fatty liver disease. Metabolites. (2022) 12(8):718. 10.3390/metabo12080718
38.
SuwałaSJunikR. Metabolic-associated fatty liver disease and the role of hormones in its aetiopathogenesis. Endokrynol Pol. (2024) 75(3):237–52. 10.5603/ep.99689
39.
CalcaterraVDegrassiITarantoSPorroCBianchiAL'assainatoSet alMetabolic dysfunction-associated fatty liver disease (MAFLD) and thyroid function in childhood obesity: a vicious circle?Children (Basel). (2024) 11(2):244. 10.3390/children11020244
40.
KouvariMValenzuela-VallejoLAxarloglouEVerrastroOPapatheodoridisGMingroneGet alThyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: a multi-centre biopsy-based observational study. Liver Int. (2024) 44(3):848–64. 10.1111/liv.15847
41.
WangXZhangBJiangR. Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights. Front Cell Infect Microbiol. (2025) 15:1467197. 10.3389/fcimb.2025.1467197
42.
SilvaYPBernardiAFrozzaRL. The role of short-chain fatty acids from gut Microbiota in gut-brain communication. Front Endocrinol (Lausanne). (2020) 11:25. 10.3389/fendo.2020.00025
43.
GoftonCUpendranYZhengMHGeorgeJ. MAFLD: how is it different from NAFLD?Clin Mol Hepatol. (2023) 29(Suppl):S17–31. 10.3350/cmh.2022.0367
44.
ChoiSYYiDYKimSCKangBChoeBHLeeYet alSevere phenotype of non-alcoholic fatty liver disease in pediatric patients with subclinical hypothyroidism: a retrospective multicenter study from Korea. J Korean Med Sci. (2021) 36(20):e137. 10.3346/jkms.2021.36.e137
45.
XueJLiCJuJLiangSet alAssociation of insulin-like growth factor 1 and metabolic parameters with mild subclinical hypothyroidism in obese boys. Sci Rep. (2025) 15(1):17017. 10.1038/s41598-025-02084-x
46.
UntalanMCrimmins NAYatesKPMencin AAXanthakos SAThakerVVet alPrevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: an observational study. Hepatology. (2025) 82(1):155–64. 10.1097/HEP.0000000000001095
47.
NicholsPHPanYMayBPavlicovaMRauschJCMencinAAet alEffect of TSH on non-alcoholic fatty liver disease (NAFLD) independent of obesity in children of predominantly hispanic/latino ancestry by causal mediation analysis. PLoS One. (2020) 15(6):e0234985. 10.1371/journal.pone.0234985
48.
KaltenbachTEGraeterTOeztuerkSHolznerDKratzerWWabitschMet alThyroid dysfunction and hepatic steatosis in overweight children and adolescents. Pediatr Obes. (2017) 12(1):67–74. 10.1111/ijpo.12110
49.
LiuLYuYZhaoMZhengDZhangXGuanQet alBenefits of levothyroxine replacement therapy on nonalcoholic fatty liver disease in subclinical hypothyroidism patients. Int J Endocrinol. (2017) 2017:5753039. 10.1155/2017/5753039
50.
MahranZGOsmanSMAbdelmawgodAMakhloufNAHassanEAMoustafaEFet alInfluence of levothyroxine replacement on metabolic dysfunction-associated steatotic liver disease and dyslipidemia in subclinical hypothyroidism: insights from a randomized controlled study. Egypt J Intern Med. (2025) 37(1):29. 10.1186/s43162-025-00415-y
51.
KorevaarTIMMediciMVisserTJPeetersRP. Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nat Rev Endocrinol. (2017) 13(10):610–22. 10.1038/nrendo.2017.93
52.
MarfellaRFerraraccioFRizzoMRPortogheseMBarbieriMBasilioCet alInnate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab. (2011) 96(4):1015–20. 10.1210/jc.2010-1382
53.
BruinstroopEDalanRCaoYBeeYMChandranKChoLWet alLow-Dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes Mellitus and NAFLD. J Clin Endocrinol Metab. (2018) 103(7):2698–706. 10.1210/jc.2018-00475
54.
ZhaoMXieHShanHZhengZLiGLiMet alDevelopment of thyroid hormones and synthetic thyromimetics in non-alcoholic fatty liver disease. Int J Mol Sci. (2022) 23(3):1102. 10.3390/ijms23031102
55.
WangYLiuHDongFXiaoYXiaoFGeTet alAltered gut microbiota and microbial metabolism in children with hepatic glycogen storage disease: a case-control study. Transl Pediatr. (2023) 12(4):572–86. 10.21037/tp-22-293
56.
BargielPSzczukoMStachowskaLProwansPCzaplaNMarkowskaMet alMicrobiome metabolites and thyroid dysfunction. J Clin Med. (2021) 10(16):3609. 10.3390/jcm10163609
Summary
Keywords
metabolic dysfunction-associated fatty liver disease (MAFLD), subclinical hypothyroidism (SCH), thyroid-stimulating hormone (TSH), insulin resistance, adolescents
Citation
Hu X, Shi W, Xu G, Li W, Yao N, Yu G and Qu J (2026) Exploring the link between metabolic dysfunction-associated fatty liver disease and subclinical hypothyroidism in adolescents: a comprehensive review. Front. Pediatr. 14:1696331. doi: 10.3389/fped.2026.1696331
Received
19 September 2025
Revised
16 November 2025
Accepted
15 January 2026
Published
16 February 2026
Volume
14 - 2026
Edited by
Michelle Plusquin, University of Hasselt, Belgium
Reviewed by
Leandro Fernández-Pérez, University of Las Palmas de Gran Canaria, Spain
Kamila Magdalena Szeliga, Medical University of Silesia, Poland
Updates
Copyright
© 2026 Hu, Shi, Xu, Li, Yao, Yu and Qu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jun Qu qujunchief@163.com Guoyong Yu 18901133535@163.com
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.